Form D · Biotechnology
Linus Biotechnology Inc.
North Brunswick, NJ · CIK 0001918153
Offering snapshot reported Aug 12, 2024 · SEC filing
- Reported sold
- $6.15M Offering amount: $10M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2024 | Initial | $6,149,995 | No comparison | 4 | SEC filing |
| May 26, 2023 | Initial | $7,999,997 | No comparison | 3 | SEC filing |
| Mar 22, 2022 | Initial | $17,496,637 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521234
Source: Form D, filed Aug 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Manish Arora | Director, Executive |
| Amol Deshpande | Director |
| Jan Glassner | Director, Executive |
| Ashok Krishnamurthi | Director |
| Rafi Syed | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
675 Us 1
North Brunswick, NJ, 08902
North Brunswick, NJ, 08902